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and CABG groups in elderly patients with DM and MVD 
in a single-center study.
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Introduction
Industrialized countries are experiencing aging socie-
ties. Japan has one of the highest life expectancies in 
the world with life expectancies of 79.6 and 86.3 years 
in Japanese men and women, respectively [1]. An aging 
society is associated with increased morbidity from ath-
erosclerotic diseases. Coronary artery disease (CAD) 
has been a critical issue that requires physicians to con-
sider appropriate treatment strategies for elderly peo-
ple who tend to have several comorbidities, including 
diabetes mellitus (DM), hypertension, and multivessel 
coronary disease (MVD) [2–5]. In the past few decades, 
several studies have been conducted comparing clini-
cal outcomes between percutaneous coronary interven-
tion (PCI) and coronary artery bypass graft (CABG) in 
patients with DM and MVD [6–8]. A recent large-scale 
randomized study demonstrated superior clinical out-
comes in patients with DM and MVD who underwent 
CABG versus PCI with drug-eluting stents (DES) [9]. 
However, elderly people were excluded in those clini-
cal studies. Therefore, there have been no comparisons 
of clinical outcomes between CABG and PCI with 
DES in elderly patients with DM and MVD. The aim of 
this study was to compare long-term clinical outcomes 
between CABG and PCI with DES in elderly patients 
with DM and MVD.
Abstract Coronary artery disease is a critical issue that 
requires physicians to consider appropriate treatment strat-
egies, especially for elderly people who tend to have sev-
eral comorbidities, including diabetes mellitus (DM) and 
multivessel disease (MVD). Several studies have been 
conducted comparing clinical outcomes between percu-
taneous coronary intervention (PCI) and coronary artery 
bypass graft (CABG) in patients with DM and MVD. How-
ever, elderly people were excluded in those clinical studies. 
Therefore, there are no comparisons of clinical outcomes 
between CABG and PCI in elderly patients with DM and 
MVD. We compared all-cause mortality between PCI with 
drug-eluting stents (DES) and CABG in elderly patients 
with DM and MVD. A total of 483 (PCI; n = 256, CABG; 
n = 227) patients were analyzed. The median follow-up 
period was 1356 days (interquartile range of 810–1884). 
The all-cause mortality rate was not significantly differ-
ent between CABG and PCI with DES groups. The CABG 
group had more patients with complex coronary lesions 
such as three-vessel disease or a left main trunk lesion. 
Older age, hemodialysis, and reduced LVEF were associ-
ated with increased long-term all-cause mortality in a mul-
tivariable Cox regression analysis. The rate of all-cause 
mortality was not significantly different between the PCI 
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We analyzed data from consecutive patients in our database 
aged 65 and older with DM and MVD who underwent a 
PCI with DES or a CABG at Juntendo University Hospital 
(Tokyo, Japan) between April 2004 and December 2008. A 
revascularization strategy for each patient was determined 
based on the patient’s background, such as age, active daily 
living, and comorbid diseases, in our heart team conference 
with cardiovascular physicians and surgeons.
Clinical outcomes
The clinical outcome was all-cause mortality. Information 
regarding outcomes was collected during clinical visits, via 
telephone interviews with the patients or from their refer-
ring physicians. Our institutional review board approved 
the protocol of this study, which was implemented in 
accordance with the principles established in the Declara-
tion of Helsinki and our institutional ethics policy.
Definitions
Based on the American Heart Association Classifica-
tion, we defined MVD as CAD when two or three vessels 
were visually assessed with more than 75 % stenosis. ACS 
was defined as unstable angina pectoris (UAP), non-ST 
segment elevation myocardial infarction (NSTEMI), or 
STEMI. UAP was defined as angina at rest or in an accel-
erating pattern with negative cardiac biomarkers, with or 
without ECG changes indicative of myocardial ischemia 
(for example, ST segment depression or transient eleva-
tion or new T-wave inversion). Myocardial infarction was 
defined as an increase (≤2-fold) in serum creatinine kinase 
and troponin T positivity. DM was defined as glycated 
hemoglobin A1c (HbA1c) with an NGSP value ≥6.5 % 
or under treatment with anti-diabetic agents or insulin. 
We converted HbA1c [Japan Diabetes Society (JDS)] val-
ues to HbA1c (NGSP) units using the following equation: 
NGSP (%) = 1.02 × JDS (%) + 0.25 % [10]. Hyperten-
sion was defined as a systolic blood pressure ≥140 mmHg 
and a diastolic blood pressure ≥90 mmHg or under treat-
ment with anti-hypertensive medications. Dyslipidemia 
was defined as triglyceride levels ≥150 mg/dL, low-density 
lipoprotein cholesterol (LDL-C) levels ≥140 mg/dL, high-
density lipoprotein cholesterol (HDL-C) levels <40 mg/
dL, or under medication dyslipidemia. We defined current 
smokers as individuals who smoked at the time of admis-
sion or who had quit within 1 year before the study period. 
Renal dysfunction was defined as an estimated glomerular 
filtration rate (eGFR) of <60 mL min−1 1.73 m2 calculated 
using the modification of diet in renal disease (MDRD) 
equation which was modified with a Japanese coefficient 
using baseline serum creatinine [11].
Statistical analyses
Continuous variables were expressed as mean values with 
standard deviations (SD). Categorical data were expressed 
as counts and percentages. Comparisons of continuous 
variables were performed with an unpaired t test or Mann–
Whitney U test. Categorical variables were analyzed by 
Chi-squared tests or Fisher’s exact probability test. Unad-
justed cumulative event rates were estimated by Kaplan–
Meier methods and compared using a log-rank test between 
the groups. To identify predictors of outcomes, a univari-
able Cox regression analysis was performed including age, 
gender, BMI, hypertension, dyslipidemia, current smoking, 
prior MI, LDL-C, HDL-C, TG, hemoglobin A1c, hemodi-
alysis, left ventricular ejection fraction, eGFR, and CABG 
as independent variables. Hazard ratios (HR) and 95 % 
confidence intervals were also calculated. Variables with 
p < 0.1 in the analysis were analyzed by multivariable Cox 
regression analysis. A p value < 0.05 was considered to be 
statistically significant. All the data were analyzed using 
JMP version 10.0 for Windows (SAS Institute, Cary, NC, 
USA).
Results
A total of 483 (PCI; n = 256, CABG; n = 227) patients 
were analyzed in this study. The median follow-up period 
was 1356 days (interquartile range of 810 to 1884). The 
baseline characteristics are shown in Table 1. The mean 
age was similar between the two groups (72.7 ± 5.3 and 
72.7 ± 5.3 in the PCI and CABG groups, respectively). 
The percentage of male gender was higher in the PCI 
group. The patients in the CABG group were more likely 
to have a prior myocardial infarction, reduced LV function, 
and triple-vessel disease or left main trunk lesion, while 
the PCI group included more patients undergoing hemodi-
alysis. The lipid profiles were similar between the groups. 
The glycated hemoglobin value was higher in the CABG 
group. The medications for secondary prevention of coro-
nary artery disease, such as DAPT, statin, ACE-I/ARB, and 
β-blocker, were administered in more patients in the PCI 
group than the CABG group. The percentage of left inter-
nal thoracic artery (LITA) use was 98.2 %. The rates of 
bilateral internal thoracic artery (BITA) use and total artery 
revascularization (TAR) were 55.9 and 26.4 %, respectively 
(Table 1).
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Clinical outcomes
All-cause mortality was observed in 31 patients (12.1 %) in 
the PCI group and 37 (16.3 %) in the CABG group (Fig. 1). 
The cardiovascular mortality rates were 3.1 and 2.2 % in 
the PCI and CABG groups, respectively. The event-free 
curves for all-cause mortality were in favor of the CABG 
group, although the difference was not statistically signifi-
cant (Fig. 2). The univariable Cox regression analysis for 
all-cause mortality showed that older age, hemodialysis, 
and reduced LVEF were associated with an increase in the 
long-term all-cause mortality. The CABG was not asso-
ciated with the clinical outcome in the univariable Cox 
regression analysis. No association was observed between 
the use of LITA, BITA, or TAR and the clinical outcome in 
the analysis. After adjusting for confounding variables, age, 
hemodialysis, and LVEF remained significant (Table 2).
Discussion
The main results of the study were as follows: (1) The all-
cause mortality rate was not significantly different between 
the CABG and PCI with DES in the patients ≥65 years old, 
DM, and MVD. (2) The patients who underwent CABG 
had more complex coronary lesions, such as three-vessel 
disease or left main trunk lesion. (3) Older age, hemodi-
alysis, and reduced LVEF were associated with an increase 
Table 1  Baseline 
characteristics
NA not applicable, BMI body mass index, MI myocardial infarction, LDL-C low-density lipoprotein choles-
terol, HDL-C high-density lipoprotein cholesterol, HbA1c glycated hemoglobin, LVEF left ventricular ejec-
tion fraction, eGFR estimated glomerular filtration rate, ACE-I angiotensin-converting enzyme inhibitor, 
ARB angiotensin receptor blocker
PCI group, (N = 256) CABG group, (N = 227) p value
Age 72.7 ± 5.3 72.7 ± 5.1 0.9
Male, n (%) 200 (78.1) 155 (68.3) 0.017
BMI, kg/m2 24.0 ± 3.3 23.8 ± 3.4 0.7
Hypertension, n (%) 197 (77.0) 168 (74.0) 0.45
Dyslipidemia, n (%) 196 (76.6) 156 (68.7) 0.053
Smoking, n (%) 180 (58.6) 142 (62.6) 0.2
Family history, n (%) 71 (27.7) 40 (17.6) 0.008
Hemodialysis, n (%) 19 (7.4) 3 (1.3) 0.0013
Prior MI, n (%) 76 (29.8) 101 (44.5) 0.0019
Total cholesterol, mg/dL 182.8 ± 31.7 179.0 ± 39.3 0.2
LDL-C, mg/dL 111.2 ± 26.4 106.4 ± 27.9 0.055
HDL-C, mg/dL 44.9 ± 13.1 46.0 ± 13.0 0.36
Triglyceride, mg/dL 134.0 ± 73.5 133.3 ± 66.7 0.9
HbA1c (NGSP), % 7.0 ± 1.1 7.3 ± 1.1 0.015
LVEF, % 61.9 ± 11.5 56.7 ± 12.9 <0.001
eGFR, mL/min/1.73 m2 64.1 ± 25.0 60.3 ± 27.3 0.1
Medication, (%)
 Aspirin 97.7 93.8 0.08
 Dual antiplatelet therapy 97.7 15.3 <0.0001
 Statin 69.8 23.7 <0.0001
 ACE-I/ARB 51.4 28.7 <0.0001
 β-blocker 51.4 33.2 <0.0001
Diseased vessel, (%)
 Triple-vessel disease, (%) 53.5 74.0 <0.0001
 Left main trunk, (%) 19.6 37.4 0.0002
 Left internal thoracic artery, (%) NA 223 (98.2) NA
 Bilateral internal thoracic artery, (%) NA 127 (55.9) NA
 Total arterial revascularization, (%) NA 60 (26.4) NA
Type of coronary artery disease 0.0005
Stable angina pectoris 88.3 76.2
Acute coronary syndrome 11.7 23.8
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in long-term all-cause mortality in the multivariable Cox 
regression analysis.
A meta-analysis comparing PCI and CABG in patients 
with DM and MVD demonstrated that there was no signifi-
cant difference in mortality or MI between the two proce-
dures [12]. In contrast, a large-scale randomized study with 
1900 patients with DM and MVD showed that mortality 
and MI rates were better with the CABG procedure than 
PCI [9]. However, studies comparing PCI and CABG often 
exclude elderly patients, who are considered to have more 
comorbidities and higher mortality rates associated with 
revascularization therapy [2, 13, 14]. Thus, these results do 
not reflect clinical practices in an aging society. Although 
several studies have investigated the comparative effec-
tiveness between PCI and CABG in elderly patients [15, 
16], the study populations were not diabetic patients with-
out MVD, but with left main coronary artery disease. Our 
study is novel because it focused on elderly patients with 
DM and MVD.
In this study, the all-cause mortality rate was not differ-
ent between the CABG and PCI with DES groups, despite 
the higher-risk profiles of the patients in the CABG group 
in terms of prior myocardial infarctions, reduced LV func-
tion, and triple-vessel disease or left main trunk lesion. A 
possible explanation is that CABG not only is a revasculari-
zation therapy for focal coronary artery lesions but may also 
have a beneficial effect on a wide range of myocardial per-
fusion because of increased blood flow through the grafts. 
Thus, CABG might lead to favorable clinical outcomes 
by improving cardiac function, although we had no data 
regarding improvement in cardiac function, such as LVEF, 
following the CABGs. The other reason for the lack of sig-
nificant differences in all-cause mortality was that the deci-
sion of revascularization strategy for each patient that was 
determined in our heart team conference by cardiovascular 
physicians and surgeons was appropriate. Because CABG is 
highly invasive in contrast to PCI, selecting a revasculariza-
tion therapy depends not only on complexity of the lesion 
but also on a patient’s medical history and comorbidities. 
In previous clinical trials, higher-risk surgical patients, such 
as the elderly and those with more comorbid diseases, were 
excluded. Therefore, selecting a revascularization therapy 
for a patient with CAD and DM requires a more thorough 
discussion of the patient’s coronary anatomical features and 
lesion characteristics, age, comorbid conditions, cardio-
pulmonary function, and frailty. The thorough discussion 
Fig. 1  All-cause mortality rate was 12.1 and 16.3 % in PCI- and 
CABG-treated groups, respectively. Cardiovascular mortality rate was 
3.1 and 2.2 % in PCI- and CABG-treated groups, respectively
Fig. 2  Cumulative event-free 
survival curves for all-cause 
mortality. Kaplan–Meier curves 
for all-cause mortality show no 
significant difference between 
PCI- and CABG-treated groups, 
respectively
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among the cardiovascular physicians and surgeons to decide 
a revascularization strategy for each patient could affect the 
prognosis following each revascularization, although the 
effect of these heart team discussions on clinical outcomes 
was not assessed in this study.
In the multivariable Cox regression analysis, older age, 
hemodialysis, and low LVEF were associated with all-
cause mortality. A previous report that has demonstrated the 
prognostic impact of reduced LVEF on clinical outcomes 
in patients with coronary artery disease [17] supports our 
findings. Hemodialysis has also been demonstrated to be 
associated with worse clinical outcomes following coro-
nary revascularization [18–20].
Limitations
First, heterogeneity between the PCI-treated group and 
CABG-treated group had a potential effect on the results 
of this study, although the Cox regression analysis was 
performed to minimize the effect of the different patients’ 
background between two groups. In addition, undeter-
mined factors might have affected the results because our 
data were derived from a longitudinal cohort. Second, other 
endpoints, including target vessel revascularization and 
cerebral infarction, were not assessed in the present study 
because all the study population was not followed by our 
institution after discharge. The outcome data of the patients 
were limited to mortality by their referring doctors who 
performed the follow-up, which was a major limitation 
considering that almost all clinical trials comparing PCI 
and CABG assessed the events as primary or secondary 
endpoints. Third, although the revascularization strategy 
was determined considering the patient’s background and 
comorbid diseases in the conference with cardiovascular 
physicians and surgeons, a quantitative assessment of coro-
nary artery lesion complexity or patient background, such 
as SYNTAX2 or EuroScore, was not performed. Finally, 
this was a retrospective study in a single institution with a 
relatively small number of study population, and therefore 
this study was underpowered for the clinical outcome and 
the results may not be directly generalizable.
Conclusions
The rate of all-cause mortality was not significantly differ-
ent between PCI and CABG in elderly patients with DM 
and MVD in this single-center study. Age, HD, and LVEF 
were significantly associated with long-term clinical out-
comes in this population.
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